Abstract: Disclosed herein are methods for identifying the effects, including off target effect, of genomic modification of primary cells. These methods are performed with high accuracy suitable for validating therapeutic T-cell engineering approaches.

Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Abstract: Disclosed herein are antigenic peptide-MHC molecules, termed comPACTs, and methods of producing such molecules. Also disclosed herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells.

Abstract: Disclosed herein are antigenic peptide-MHC molecules, termed comPACT2.0 polypeptides, and methods of producing such molecules. Also disclosed herein are methods of producing libraries of comPACT2.0 polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells.

Abstract: The present disclosure relates to methods for sequencing and identifying T cell receptors (TCR). The methods include the use of template-switching oligonucleotides (TSOs) and as well as result in improving yield and reducing complexity compared to standard methods.

Abstract: Methods of assessing or evaluating functional properties of T cell therapeutic products are described herein.

Abstract: The present disclosure provides novel artificial antigen presenting cells (aAPCs). The aAPCs disclosed herein comprise a liposome comprising a phospholipid and a stimulatory ligand displayed on the outer surface of the liposome. The aAPCs of the present disclosure can be used as an “off the shelf” tool to activate and expand a T cell of interest. Also, the present disclosure provides methods of activating a T cell and manufacturing a T cell therapy product using the aAPCs disclosed herein.